Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study probes Glucagon's hidden role in blood sugar after gastric bypass

NCT ID NCT07212868

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the hormone glucagon influences blood sugar in people who have had bariatric surgery and those who haven't. Researchers will use an experimental drug called REMD-477 to block glucagon and measure changes in glucose metabolism. The goal is to better understand why some people develop blood sugar problems after surgery. The study involves 150 adults aged 18 to 65 who are non-diabetic.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REMD-477 (a monoclonal antibody that blocks glucagon) and glucagon infusion
What this could lead to
If successful, this study could help explain why some people develop diabetes after bariatric surgery and point toward new treatments.
What could go wrong
This is an early-phase study with only 150 participants, so results may not apply to everyone. The drug REMD-477 is investigational and not yet FDA-approved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated informed consent form from participant. 2. Male or female, ≤65 and ≥18 years old 3. Subjects with history of gastric bypass surgery and sleeve gastrectomy more than a year since surgery and non-surgical subjects without history of gastrointestinal (GI) surgery 4. HbA1c ≤6% 5. Willing to adhere to the study intervention regimen 6. Female subjects of childbearing potential must have a negative pregnancy test at screening and all the study visits, and must not be lactating 7. Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions during the study.It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Exclusion Criteria: 1. Diabetes 2. Pregnancy/lactation 3. Hgb \<11 4. Current GI obstruction or chronic diarrhea 5. Subjects who are not within the age range of 18- 65 years. 6. Evidence of active cardiorespiratory, hepatic, gastrointestinal or renal disease. 7. History of allergy to the administered drugs. 8. History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate or affect the interpretation of the results of the study and/or any subject unable or unwilling to follow study procedures. 9. Substance dependence or history of alcohol abuse and/or excess alcohol intake 10. Patients on ketogenic diet 11. Prisoners or institutionalized individuals 12. AST (SGOT) \> 3 times upper limit of normal 13. ALT (SGPT) \> 3 times upper limit of normal 14. History of clinical hypoglycemia documents based on Whipples' triad (ONLY for Aim 2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-diabetic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Texas Diabetes Institute - University Health System

    RECRUITING

    San Antonio, Texas, 78207, United States

  • University of Texas San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.